Lungs News and Research

RSS

FDA clears Olerup SSP’s Taq-polymerase-free HLA typing kit for sale in the U.S.

Olerup SSP, a wholly owned subsidiary of LinkMed (STO:LMED), has had its Taq-polymerase-free HLA typing kit registered and cleared by the FDA. This means that Olerup SSP’s entire product range for HLA typing, with or without Taq polymerase, can now be marketed and sold to a greater number of healthcare centers in North America.

15 Sep 2009

American Lung Association urges families to get immunized against seasonal influenza

The American Lung Association is intensifying its seasonal influenza public education initiative to urge families to get vaccinated as soon as possible. The Faces of Influenza campaign aims to ensure Americans get immunized against seasonal influenza, which each year causes an estimated 36,000 deaths and over 226,000 hospitalizations from the virus and its related complications.

15 Sep 2009

Gentic circuits that cause mucous hyper-production identified

Scientists have identified the main genetic switch that causes excessive mucous in the lungs, a discovery that one day could ease suffering for people with chronic lung diseases like asthma and cystic fibrosis, or just those fighting the common cold.

15 Sep 2009

Risk for patients contracting pneumonia increases threefold when treated with pantoprazole: Study

A popular stomach-acid reducer used to prevent stress ulcers in critically ill patients needing breathing machine support increases the risk of those patients contracting pneumonia threefold, according to researchers at Wake Forest University School of Medicine.

15 Sep 2009

miR-200 supression shifts primary lung cancer to metastatic disease

Primary lung cancer shifts to metastatic disease by suppressing a family of small molecules that normally locks the tumor in a noninvasive state, researchers at The University of Texas M. D. Anderson Cancer Center report in the Sept. 15 edition of Genes and Development.

15 Sep 2009

Genetic switch that causes excessive mucus in the lungs identified

Scientists have identified the main genetic switch that causes excessive mucus in the lungs, a discovery that one day could ease suffering for people with chronic lung diseases like asthma and cystic fibrosis, or just those fighting the common cold.

15 Sep 2009

Phase 2b trial of Mpex's Aeroquin with PARI Pharma's eFlow Nebulizer System successful

Mpex Pharmaceuticals, Inc. reported positive top line results from a Phase 2b clinical trial with Aeroquin, a novel aerosol formulation of levofloxacin delivered by an optimized Investigational eFlow Nebulizer System from PARI Pharma. In the Mpex cystic fibrosis trial, nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa in sputum after 28 days of dosing versus placebo.

15 Sep 2009

Hispanic/Latino Americans have a unique cancer risk profile, says report

The latest edition of Cancer Facts & Figures for Hispanics/Latinos reports that Hispanic/Latino Americans -the largest, fastest-growing, and youngest minority in the United States-have a unique cancer risk profile that requires a targeted approach to cancer prevention.

15 Sep 2009

Study reveals that daily bathroom showers may deliver pathogenic bacteria

While daily bathroom showers provide invigorating relief and a good cleansing for millions of Americans, they also can deliver a face full of potentially pathogenic bacteria, according to a surprising new University of Colorado at Boulder study.

15 Sep 2009

Nebulized interferon-gamma helps minimize transmissibility of TB

A new study published in the September 15, 2009, issue of PLoS ONE found that patients with cavitary pulmonary tuberculosis receiving anti-TB medications supplemented with nebulized interferon-gamma have fewer bacilli in the lungs and less inflammation, thereby reducing the transmissibility of tuberculosis in the early phase of treatment.

15 Sep 2009

Aeolus commences second study of AEOL 10150 against Acute Radiation Syndrome

Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today the initiation of a second study, in mice, to determine the optimal length of treatment with AEOL 10150 when used as a countermeasure to Acute Radiation Syndrome (ARS) in the lungs. This study, led by Zeljko Vujaskovic, M.D. Ph.D. of Duke University, is designed to build on the recently completed study that demonstrated the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation, and determine the most effective duration of delivery for treatment after exposure.

14 Sep 2009

Clinical studies reveal treatment with pirfenidone is safe and well-tolerated

InterMune, Inc. (Nasdaq: ITMN) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, Germany.

14 Sep 2009

Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the first patient has been dosed in a Phase 1/2 study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1. CDX-1401 is a fully human monoclonal antibody designed to selectively deliver the NY-ESO-1 antigen to dendritic cells to generate a robust immune response against cancer cells expressing NY-ESO-1.

14 Sep 2009

Zabecor Pharmaceuticals initiates Phase II clinical trial of its Excellair asthma drug

ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.

14 Sep 2009

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas aeruginosa density.

14 Sep 2009

Data from Phase 1 and Phase 2a studies of inhaled liposomal ciprofloxacin to be presented at ERS Congress

Aradigm Corporation (OTCBB: ARDM) ("Aradigm") today announced it is presenting data from its Phase 1 and Phase 2a studies at the ERS Annual Congress in Vienna, Austria, September 12-16, 2009.

14 Sep 2009

Clinical study results of DAS181 against H1N1 influenza presented

NexBio, Inc. announced today the presentation of two studies of DAS181 activity against H1N1 influenza and NAI-resistant influenza at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting on Sunday, September 13, 2009, in San Francisco, CA.

14 Sep 2009

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC).

14 Sep 2009

Flu Clinic Locator makes it easy for people to locate the most convenient clinic to get their seasonal flu vaccine

The American Lung Association is making it easier for people to get their seasonal flu vaccine this year with the availability of its 2009-2010 Flu Clinic Locator. The largest online directory of public seasonal influenza vaccination clinics is now available at www.flucliniclocator.org.

11 Sep 2009

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, continues to drive the global effort to ensure patients receive personalized cancer therapies. A total of 17 abstracts concerning Merck Serono oncology treatments will be presented at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), to be held in Berlin from 20-24 September 2009.

11 Sep 2009

Lungs News and Research

FDA clears Olerup SSP’s Taq-polymerase-free HLA typing kit for sale in the U.S.

American Lung Association urges families to get immunized against seasonal influenza

Gentic circuits that cause mucous hyper-production identified

Risk for patients contracting pneumonia increases threefold when treated with pantoprazole: Study

miR-200 supression shifts primary lung cancer to metastatic disease

Genetic switch that causes excessive mucus in the lungs identified

Phase 2b trial of Mpex's Aeroquin with PARI Pharma's eFlow Nebulizer System successful

Hispanic/Latino Americans have a unique cancer risk profile, says report

Study reveals that daily bathroom showers may deliver pathogenic bacteria

Nebulized interferon-gamma helps minimize transmissibility of TB

Aeolus commences second study of AEOL 10150 against Acute Radiation Syndrome

Clinical studies reveal treatment with pirfenidone is safe and well-tolerated

Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate

Zabecor Pharmaceuticals initiates Phase II clinical trial of its Excellair asthma drug

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

Data from Phase 1 and Phase 2a studies of inhaled liposomal ciprofloxacin to be presented at ERS Congress

Clinical study results of DAS181 against H1N1 influenza presented

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Flu Clinic Locator makes it easy for people to locate the most convenient clinic to get their seasonal flu vaccine

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News